15 results on '"Hongyan Wang"'
Search Results
2. Shuyu capsules relieve liver-qi depression by regulating ERK-CREB-BDNF signal pathway in central nervous system of rat.
- Author
-
HONGYAN WANG, YINGQUAN ZHANG, HELOU LI, WEI ZENG, and MINGQI QIAO
- Subjects
- *
CENTRAL nervous system , *RATS , *PHARMACEUTICAL encapsulation , *NEUROTROPHIC functions , *ENZYME-linked immunosorbent assay , *PSYCHOLOGY - Abstract
The purpose of this study was to investigate the possible therapeutic mechanism of Shuyu capsules in liver-qi depression. Liver-qi depression rats were prepared based on chronic unpredictable mild stress (CUMS) and delayed constraint. Rats were gavaged with Shuyu capsule, fluoxetine, Radix Bupleuri and Radix Paeoniae Alba to constrct rat models. Body weight test, sucrose preference test and open-field test were applied to test rat models. Western blot analysis and quantitative real-time PCR was applied to determine the relative expression of extracellular signal-regulated protein kinase (ERK), cyclic AMP response element binding protein (CREB) and brain-derived neurotrophic factor (BDNF) in hippocampus and frontal lobe tissues. ELISA was used to detect the content of BDNF in serum. Body weight, sugar intake and total distance were significantly decreased in depression group compared with control. The four drugs significantly increased levels of these factors. Compared with control group, ERK, CREB and BDNF expression were significantly decreased in depression group in both hippocampus and frontal lobe tissues at both mRNA and protein level. Shuyu capsule and fluoxetine group showed a significant increase in the expression of ERK, CREB and BDNF at mRNA, p-ERK and p-BDNF at protein level. Compared with Radix Paeoniae Alba, Radix Bupleuri were better in the rescue of ERK, CREB and BDNF expression. In conclusion, the pathogenesis of liver-qi depression associated with lower expression of ERK, CREB and BDNF in hippocampus and frontal. Shuyu capsule and main constitution alleviated the depressive-like behaviors and reversed the disruptions of the p-ERK, p-CREB and BDNF in stressed rats. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
3. Expression of the tumor suppressor gene p16, and lymph node metastasis in patients with ovarian cancer.
- Author
-
HONGYAN WANG, JINGFANG ZHENG, QIANG LI, MIN ZHOU, DONGMEI AI, and HUI ZHANG
- Subjects
- *
OVARIAN cancer , *P16 gene , *GENE expression , *METASTASIS , *WESTERN immunoblotting , *PROGNOSIS - Abstract
This study examined the relationship between the expression of p16, a tumor suppressor gene, and lymph node metastasis, as well as patient prognosis, in cases with ovarian cancer. SKOV-3, an ovarian cancer cell line, and IOSE80, a normal human ovarian cell line, were selected for testing. Western blot analysis was used to detect the p16 expression in ovarian cell culture samples. In the study, 20 cases with normal ovarian tissue and 64 cases with ovarian cancer tissue, including 38 cases with lymph node metastasis and 26 cases without lymph node metastasis, were also selected for testing. Immunohistochemical techniques were used to detect the expression of p16 protein in ovarian tissue samples. The influence of p16 protein on SKOV-3 cell invasion ability was studied using p16 gene high-expression vector transfection. Clinical and prognosis data were summarized and the influence of p16 on patient prognosis was analyzed through Kaplan-Meier single-factor survival analysis. The results showed that p16 expression in SKOV-3 was decreased significantly compared with that in IOSE80. The positive rate of p16 protein expression in ovarian cancer tissue was notably decreased compared with that in normal ovarian tissue. The positive rate of p16 protein expression in ovarian cancer tissue of patients with lymph node metastasis was significantly decreased compared with that of patients without lymph node metastasis. Therefore, transfection of the p16 gene significantly inhibited the protein expression and invasion ability of p16 in SKOV-3. Correlation analyses between p16 and survival prognosis demonstrated that lower expression of p16 was negatively correlated with the prognosis of patients with ovarian cancer. Overall, the abnormal expression of p16 in ovarian cancer is associated with an increased invasion ability of ovarian cancer and the lower expression of p16 in tissue samples indicates a poor prognosis in patients with ovarian cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
4. Identification and characterization of miR-96, a potential biomarker of NSCLC, through bioinformatic analysis.
- Author
-
TONGHUI CAI, JIE LONG, HONGYAN WANG, WANXIA LIU, and YAJIE ZHANG
- Published
- 2017
- Full Text
- View/download PDF
5. A multi-shRNA vector enhances the silencing efficiency of exogenous and endogenous genes in human cells.
- Author
-
YANJIE WENG, YING SHI, XI XIA, WENJUAN ZHOU, HONGYAN WANG, and CHANGYU WANG
- Subjects
SMALL interfering RNA ,RNA interference ,CANCER genetics ,GENE silencing ,GENE targeting ,DOWNREGULATION ,PILOT projects - Abstract
RNA interference (RNAi) is a powerful technology for suppressing gene function. In most studies, small interfering RNAs (siRNAs) consist of one short hairpin RNA (shRNA) and, therefore, are often unable to achieve loss-of-function of their target genes. In the current study, an RNAi vector containing three shRNAs under the control of three RNA polymerase III U6 promoters was constructed. RNAi vectors containing one or two shRNAs were generated for comparisons. A pilot study targeting exogenously expressed DsRed in the HEK293 cell line revealed promising effects and a high selectivity for the multi-shRNA RNAi vector. Akt2 is constitutively expressed in cultured SKOV3 human ovarian cancer cells, and the multi-shRNA RNAi vector showed a strong efficiency for downregulating the expression of Akt2 in these cells, with no apparent interferon response. In addition, the Akt2-3shRNA vector, containing three shRNAs targeting Akt2, showed the best effect of all the shRNA vectors in reversing paclitaxel-induced resistance in SKOV3 cells. This study developed a widely applicable resource for enhancing the efficiency of gene silencing and a novel technique for performing complex loss-of-function screens in mammalian cells. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
6. SEMA3B improves the survival of patients with esophageal squamous cell carcinoma by upregulating p53 and p21.
- Author
-
HONG TANG, YUFENG WU, MING LIU, YANRU QIN, HAIYING WANG, LILI WANG, SHAOMEI LI, HUI ZHU, ZHENG HE, JUNPENG LUO, HONGYAN WANG, QIMING WANG, and SUXIA LUO
- Published
- 2016
- Full Text
- View/download PDF
7. HSP60 mediates the neuroprotective effects of curcumin by suppressing microglial activation.
- Author
-
FEIJIA DING, FAN LI, YUNHONG LI, XIAOLIN HOU, YI MA, NAN ZHANG, JIAO MA, RUI ZHANG, BING LANG, HONGYAN WANG, and YIN WANG
- Subjects
CURCUMIN ,MICROGLIA ,LIPOPOLYSACCHARIDES ,HEAT shock proteins ,TOLL-like receptors ,THERAPEUTICS - Abstract
Curcumin has anti-inflammatory and antioxidant properties and has been widely used to treat or prevent neurodegenerative diseases. However, the mechanisms underlying the neuroprotective effects of curcumin are not well known. In the present study, the effect of curcumin on lipopolysaccharide (LPS)-stimulated BV2 mouse microglia cells was investigated using enzyme-linked immunosorbent assays of the culture medium and western blotting of cell lysates. The results showed that curcumin significantly inhibited the LPS-induced expression and release of heat shock protein 60 (HSP60) in the BV2 cells. The level of heat shock factor (HSF)-1 was upregulated in LPS-activated BV2 microglia, indicating that the increased expression of HSP60 was driven by HSF-1 activation. However, the increased HSF-1 level was downregulated by curcumin. Extracellular HSP60 is a ligand of Toll-like receptor 4 (TLR-4), and the level of the latter was increased in the LPS-activated BV2 microglia and inhibited by curcumin. The activation of TLR-4 is known to be associated with the activation of myeloid differentiation primary response 88 (MyD88) and nuclear factor (NF)-κB, with the subsequent production of proinflammatory and neurotoxic factors. In the present study, curcumin demonstrated marked suppression of the LPS-induced expression of MyD88, NF-κB, caspase-3, inducible nitric oxide synthase, tumor necrosis factor-α, interleukin (IL)-1β and IL-6 in the microglia. These results indicate that curcumin may exert its neuroprotective and anti-inflammatory effects by inhibiting microglial activation through the HSP60/TLR-4/MyD88/NF-κB signaling wpathway. Therefore, curcumin may be useful for the treatment of neurodegenerative diseases that are associated with microglial activation. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
8. Investigation of potential molecular biomarkers and small molecule drugs for hepatocellular carcinoma transformed from cirrhosis.
- Author
-
FENG XIE, FANG ZHU, ZAIMING LU, ZHENGRONG LIU, and HONGYAN WANG
- Subjects
LIVER cancer ,CIRRHOSIS of the liver ,GENE expression ,ETIOLOGY of cancer ,BIOMARKERS ,ESTRADIOL ,ACETAMINOPHEN ,BISPHENOLS - Abstract
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in China and the third leading cause of cancer-associated morality. The aim of the present study was to investigate and analyze differentially-expressed genes (DEGs) between cirrhosis and HCC, in order to screen the key genes involved in the transformation from cirrhosis to HCC and provide novel targets for the diagnosis and treatment of HCC in patients with cirrhosis. The gene expression profile, GSE17548, was obtained from Gene Expression Omnibus database and the DEGs were identified by LIMMA package in R language. Kyoto Encyclopedia of Genes and Genomes and gene ontology biology process analysis were performed for the DEGs. Differential co-expression network (DEN) analysis was conducted and the network was visualized using Cytoscape. Small molecule drugs were also screened from the Comparative Toxicogenomics Database for higher degree DEGs. A total of 95 DEGs were obtained, including 46 upregulated and 49 downregulated genes. The upregulated DEGs were primarily involved in biological processes and pathways associated with the cell cycle, while the downregulated DEGs were primarily involved in immune-associated biological processes. A total of 22 key DEGs were identified by DEN analysis, which distinguished HCC from cirrhosis samples. Furthermore, estradiol, benzo(a)pyrene, acetaminophen, copper sulfate and bisphenol A were identified as the five most associated chemicals to these 22 DEGs. In conclusion, the hub genes and chemicals identified by the present study may provide a theoretical basis for additional research on diagnosis and treatment of HCC transformed from cirrhosis. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
9. Knockdown of ANXA1 suppresses the biological behavior of human NSCLC cells in vitro.
- Author
-
YING FANG, XIAOYING GUAN, TONGHUI CAI, JIE LONG, HONGYAN WANG, XIAOBIN XIE, and YAJIE ZHANG
- Subjects
ANNEXINS ,CANCER ,TUMORS ,RNA interference ,LUNG cancer - Abstract
Annexin A1 (ANXA1) is a member of the annexin superfamily. Previous studies have reported that ANXA1 is highly expressed in various types of malignant tumor; however, its role in the progression of non-small cell lung cancer (NSCLC) remains to be fully clarified. The present study aimed to investigate the oncogenic role of ANXA1 in NSCLC cells in vitro. RNA interference was used to downregulate ANXA1 expression in A549 and H1299 cells using a small interfering RNA lentiviral vector. Subsequently, cell proliferation and migration were detected using Cell Counting kit-8, clone formation, wound healing and Transwell chamber assays. Successful transfection was confirmed using fluorescence microscopy, which demonstrated that ANXA1 had been efficiently inhibited. ANXA1 knockdown suppressed the proliferation, migration and invasion of NSCLC cells. In conclusion, the present study provided evidence suggesting that ANXA1 may contribute to the growth and invasion of NSCLC cell lines, and ANXA1 may be exploited as an in vitro therapeutic target for the treatment of NSCLC. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
10. Isoalantolactone induces autophagic cell death in SKOV3 human ovarian carcinoma cells via upregulation of PEA-15.
- Author
-
ZHIYONG WENG, HONGGUO GAO, JIEHUA HU, YONGGANG FAN, HONGYAN WANG, and LIHUA LI
- Published
- 2016
- Full Text
- View/download PDF
11. Knockdown of myosin VI by lentivirus-mediated short hairpin RNA suppresses proliferation of melanoma.
- Author
-
HUI LI, FUSHENG ZHOU, HONGYAN WANG, DA LIN, GANG CHEN, XIANBO ZUO, LIANGDAN SUN, XUEJUN ZHANG, and SEN YANG
- Subjects
MYOSIN ,PROSTATE cancer ,OVARIAN cancer ,MELANOMA ,RNA - Abstract
Myosin VI has been reported to be associated with the progression of ovarian and prostate cancer. The aim of the present study was to reveal the role of myosin VI in the proliferation of melanoma. Briefly, lentivirus-mediated short hairpin RNA (shRNA) was designed specifically to silence myosin VI in A375 and A431 cell lines. Expression levels of myosin VI were then analyzed in the two cell lines by quantitative polymerase chain reaction and western blot analyses. Cell viability was assessed using MTT and colony formation assays. In addition, the cell cycle distribution was determined by flow cytometry. The results demonstrated that knockdown of myosin VI significantly suppressed melanoma cell viability and proliferation, and induced cell cycle arrest in G0/G1 phase. To the best of our knowledge, the present study was the first to assess the role of myosin VI in the growth of melanoma. Knowledge of the underlying mechanism of the role myosin VI in skin cancer cells may aid in the development of novel methods of melanoma diagnosis and therapy in the future. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
12. P2X7R is involved in the progression of atherosclerosis by promoting NLRP3 inflammasome activation.
- Author
-
KUANG PENG, LUSHAN LIU, DANGHENG WEI, YUNCHENG LV, GANG WANG, WENHAO XIONG, XIAOQING WANG, ALTAF, AFRASYAB, LILI WANG, DAN HE, HONGYAN WANG, and PENG QU
- Published
- 2015
- Full Text
- View/download PDF
13. Effect and mechanism of Src tyrosine kinase inhibitor sunitinib on the drug-resistance reversal of human A549/DDP cisplatin-resistant lung cancer cell line.
- Author
-
KE ZHANG, XIAN WANG, and HONGYAN WANG
- Subjects
DRUG resistance in cancer cells ,CANCER chemotherapy ,LUNG cancer treatment ,PROTEIN-tyrosine kinase inhibitors ,CISPLATIN ,CELL lines - Abstract
The development of tumor cell drug resistance is the primary reason for treatment failure in lung cancer chemotherapy. Therefore, overcoming multidrug resistance is currently an urgent issue to be addressed in lung cancer treatment. Sunitinib is a tyrosine kinase inhibitor with confirmed inhibitory effects on tumor growth and metastasis; however, the effects of sunitinib and mechanisms of action in lung cancer multidrug resistance are yet to be determined. The present study was designed to examine the effects of sunitinib and the mechanisms underlying lung cancer multidrug resistance. It was observed that sunitinib was able to improve the sensitivity of A549/DDP lung cancer cells to cisplatin, enhance tumor apoptosis, arrest the cell cycle in G0/G1 phase, upregulate intracellular Rh-123 content, downregulate the expression of P-glycoprotein, multidrug resistance protein 1, multidrug resistance-associated protein 1, lung resistance protein, glutathione-S-transferase, ERCC1, survivin and Bcl-2 in tumor cells, phosphorylation of AKT and extracellular signal-regulated kinase (ERK), glutathione activity, and transcriptional activity of nuclear factor-κB, Twist, Snail and AP-1. The results demonstrated that sunitinib was able to reverse the multidrug resistance of A549/DDP lung cancer cells, which was possibly associated with the downregulation of multidrug resistance-associated gene expression and the inhibition of AKT and ERK phosphorylation. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
14. Scavenging of blood glutamate for enhancing brain-to-blood glutamate efflux.
- Author
-
YUNHONG LI, XIAOLIN HOU, QI QI, LE WANG, LAN LUO, SHAOQI YANG, YUMEI ZHANG, ZHENHUA MIAO, YANLI ZHANG, FEI WANG, HONGYAN WANG, WEIDONG HUANG, ZHENHAI WANG, YING SHEN, and YIN WANG
- Subjects
BRAIN injuries ,STROKE ,COFACTORS (Biochemistry) ,COENZYMES ,BLOOD enzymes ,PYRUVATES - Abstract
The presence of excess glutamate in the brain interstitial fluid characterizes several acute pathological conditions of the brain, including traumatic brain injury and stroke. It has been demonstrated that it is possible to eliminate excess glutamate in the brain by decreasing blood glutamate levels and, accordingly, accelerating the brain-to-blood glutamate efflux. It is feasible to accomplish this process by activating blood resident enzymes in the presence of the respective glutamate cosubstrates. In the present study, several glutamate cosubstrates and cofactors were studied in an attempt to identify the optimal conditions to reduce blood glutamate levels. The administration of a mixture of 1 mM pyruvate and oxaloacetate (Pyr/Oxa) for 1 h decreased blood glutamate levels by ⩽50%. The addition of lipoamide to this mixture resulted in a further reduction in blood glutamate levels of >80%. In addition, in vivo experiments showed that lipoamide together with Pyr/Oxa is able to decrease blood glutamate levels to a greater extent than Pyr/Oxa alone, and accordingly, this enhances the glutamate efflux from the brain to the blood. These results may outline a novel neuroprotective strategy with increased effectiveness for the removal of excess brain glutamate in various neurodegenerative conditions. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
15. Recurrent myoepithelial carcinoma of the submandibular gland treated by rAd-p53 combined with radiotherapy: A case report.
- Author
-
LIN YANG, XIANGXUN CHEN, HONGYAN WANG, and QINGMING SHI
- Subjects
CARCINOMA ,RADIOTHERAPY ,NECK dissection ,SUBMANDIBULAR gland ,METASTASIS ,LINEAR accelerators - Abstract
The aim of the present study was to report the case of a patient with recurrent myoepithelial carcinoma of the submandibular gland without progression for five years following treatment. A 71-year-old male patient presented to hospital with a painless swelling in the region of the right submandibular gland, and received a radical neck dissection on January 29, 2008. A nodule of ~7×4×2 cm was identified at the site of the right submandibular gland, and the pathological results revealed a diagnosis of myoepithelial carcinoma of the right submandibular gland with no lymph node metastasis. However, this case developed local recurrence with wide-spread metastasis in the lungs. Between April and October 2008, the patient underwent several treatment regimens and demonstrated no improvement following 6 cycles of chemotherapy. From then on, the patient was treated with recombinant adenoviral-p53 (rAd-p53) combined with radiotherapy using a 6 millivolt medical linear accelerator. The foci were relieved and the cancer demonstrated no signs of progression during the 5-year follow-up. rAd-p53 combined with radiotherapy was useful for treating myoepithelial carcinoma of the submandibular gland. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.